Abstract
In the present study Quality by design (QbD) principles were applied in formulating microparticles of erlotinib HCl (ERL), a lipophilic anticancer drug by spray drying. The study was done such that the QbD approach would demonstrate efficient feasibility in formulating the product and achieving the desired sustained release profile from the microparticles. After defining the quality target product profile (QTPP), the use of risk assessment by Ishikawa diagram assisted in identification of three risk factors namely the concentrations of polycaprolactone (PCL) and polyvinyl alcohol (PVA), and inlet temperature of spray dryer. A Box-Behnken design was used to study the effect of these three screened factors on particle size and drug encapsulation efficiency and sustained release duration. The multivariate DoE was able to show the impact of critical process parameters and critical material attributes on critical quality attributes (CQAs) and came out with a suitable design space which would yield the desired quality responses. The optimized formulation by the QbD approach gave promising IC50 values against the lung cancer cells (A549) indicating improved therapeutic efficacy and effective sustained release potential of the formulated microparticles.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.